| OncoImmunology | |
| Anticancer effects of anti-CD47 immunotherapy in vivo | |
| Jonathan Pol1  Sarah Lévesque1  Guido Kroemer1  Wei Xie2  Laura Mondragon2  Laurence Zitvogel2  Aitziber Buque2  Oliver Kepp2  Kristina Iribarren2  | |
| [1] INSERM U1138;Institut Gustave Roussy; | |
| 关键词: anti-cd47; therapeutic antibody; calreticulin; cancer; immune; | |
| DOI : 10.1080/2162402X.2018.1550619 | |
| 来源: DOAJ | |
【 摘 要 】
The treatment of breast cancer largely depends on the utilization of immunogenic chemotherapeutics, which, as a common leitmotif, stimulate the exposure of calreticulin (CALR) on the surface of cancer cells, thereby facilitating their recognition by dendritic cells for the uptake of tumor-associated antigens and subsequent antigen cross-presentation to cytotoxic T cells. Breast cancer cells also express the calreticulin antagonist CD47, which inhibits tumor cell phagocytosis and consequently subverts anticancer immune responses. Here, we treated carcinogen-induced or transplantable mouse models of cancer by a CD47 blocking antibody that was at least as efficient as chemotherapy and that could be favorably combined with the anthracycline mitoxantrone in the context of carcinogen-induced orthotopic breast cancers. Monotherapy by CD47 blockade led to a reduction in tumor growth and an increase in overall survival. Of note, this treatment lead to a moderate depletion of M2 macrophages as well as close-to-complete elimination of regulatory T cells from the tumor bed, suggesting a strong favorable impact of CD47 blockade on the tumor microenvironment.
【 授权许可】
Unknown